Literature DB >> 20045303

Necroptosis as an alternative form of programmed cell death.

Dana E Christofferson1, Junying Yuan.   

Abstract

The family of death receptors plays a critical role in regulating cell number and eliminating harmful or virally infected cells. Agonistic stimulation of death receptors is known to lead two alternative cell fates by either activating NF-kappaB to promote cell survival or inducing apoptosis to lead to cell death; and now a third pathway, termed necroptosis or programmed necrosis has been identified. Interestingly, a death-domain containing kinase, RIP1, is involved in mediating all three pathways, with its kinase activity specifically involved in regulating necroptosis. The availability of necrostatin-1, a specific inhibitor of RIP1 kinase, made it possible to dissect the distinct functional domains of RIP1. Recent genome-wide siRNA screens have identified multiple players of necroptosis that may interact with and/or regulate RIP1 kinase and mediate the signaling pathway and execution of necroptosis. Necroptosis and necrostatins provide an exciting new opportunity for developing new treatments for multiple human diseases involving necrosis and inflammation. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20045303      PMCID: PMC2854308          DOI: 10.1016/j.ceb.2009.12.003

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  35 in total

1.  Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury.

Authors:  Alexei Degterev; Zhihong Huang; Michael Boyce; Yaqiao Li; Prakash Jagtap; Noboru Mizushima; Gregory D Cuny; Timothy J Mitchison; Michael A Moskowitz; Junying Yuan
Journal:  Nat Chem Biol       Date:  2005-05-29       Impact factor: 15.040

Review 2.  RIP1, a kinase on the crossroads of a cell's decision to live or die.

Authors:  N Festjens; T Vanden Berghe; S Cornelis; P Vandenabeele
Journal:  Cell Death Differ       Date:  2007-03       Impact factor: 15.828

3.  Inhibition of proinflammatory and innate immune signaling pathways by a cytomegalovirus RIP1-interacting protein.

Authors:  Claudia Mack; Albert Sickmann; David Lembo; Wolfram Brune
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

4.  Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death.

Authors:  Takashi Nakagawa; Shigeomi Shimizu; Tetsuya Watanabe; Osamu Yamaguchi; Kinya Otsu; Hirotaka Yamagata; Hidenori Inohara; Takeshi Kubo; Yoshihide Tsujimoto
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

5.  Necrostatin-1 protects against glutamate-induced glutathione depletion and caspase-independent cell death in HT-22 cells.

Authors:  Xingshun Xu; Chu C Chua; Jiming Kong; Richard M Kostrzewa; Udayasankar Kumaraguru; Ronald C Hamdy; Balvin H L Chua
Journal:  J Neurochem       Date:  2007-08-30       Impact factor: 5.372

6.  Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation.

Authors:  Hongxiu Li; Masayuki Kobayashi; Marzenna Blonska; Yun You; Xin Lin
Journal:  J Biol Chem       Date:  2006-03-16       Impact factor: 5.157

7.  Targeted mass spectrometric strategy for global mapping of ubiquitination on proteins.

Authors:  Sahana Mollah; Ingrid E Wertz; Qui Phung; David Arnott; Vishva M Dixit; Jennie R Lill
Journal:  Rapid Commun Mass Spectrom       Date:  2007       Impact factor: 2.419

8.  TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death.

Authors:  You-Sun Kim; Michael J Morgan; Swati Choksi; Zheng-Gang Liu
Journal:  Mol Cell       Date:  2007-06-08       Impact factor: 17.970

9.  Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO.

Authors:  Chee-Kwee Ea; Li Deng; Zong-Ping Xia; Gabriel Pineda; Zhijian J Chen
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

10.  Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development.

Authors:  Verena Labi; Miriam Erlacher; Stephan Kiessling; Claudia Manzl; Anna Frenzel; Lorraine O'Reilly; Andreas Strasser; Andreas Villunger
Journal:  J Exp Med       Date:  2008-02-25       Impact factor: 14.307

View more
  306 in total

Review 1.  Programmed necrosis: backup to and competitor with apoptosis in the immune system.

Authors:  Jiahuai Han; Chuan-Qi Zhong; Duan-Wu Zhang
Journal:  Nat Immunol       Date:  2011-11-16       Impact factor: 25.606

Review 2.  Alternative cell death mechanisms in development and beyond.

Authors:  Junying Yuan; Guido Kroemer
Journal:  Genes Dev       Date:  2010-12-01       Impact factor: 11.361

3.  Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections.

Authors:  David M Tobin; Francisco J Roca; Sungwhan F Oh; Ross McFarland; Thad W Vickery; John P Ray; Dennis C Ko; Yuxia Zou; Nguyen D Bang; Tran T H Chau; Jay C Vary; Thomas R Hawn; Sarah J Dunstan; Jeremy J Farrar; Guy E Thwaites; Mary-Claire King; Charles N Serhan; Lalita Ramakrishnan
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

Review 4.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

5.  RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.

Authors:  Zahra Shahsavari; Fatemeh Karami-Tehrani; Siamak Salami; Mehran Ghasemzadeh
Journal:  Tumour Biol       Date:  2015-10-26

Review 6.  Cell Death Signaling.

Authors:  Douglas R Green; Fabien Llambi
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-12-01       Impact factor: 10.005

7.  Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.

Authors:  A Cougnoux; S Clifford; A Salman; S-L Ng; J Bertin; F D Porter
Journal:  Mol Genet Metab       Date:  2018-10-30       Impact factor: 4.797

8.  RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4.

Authors:  Malek Najjar; Danish Saleh; Matija Zelic; Shoko Nogusa; Saumil Shah; Albert Tai; Joshua N Finger; Apostolos Polykratis; Peter J Gough; John Bertin; Michael Whalen; Manolis Pasparakis; Siddharth Balachandran; Michelle Kelliher; Alexander Poltorak; Alexei Degterev
Journal:  Immunity       Date:  2016-07-05       Impact factor: 31.745

Review 9.  A Mitocentric View of Alzheimer's Disease.

Authors:  Hao Hu; Chen-Chen Tan; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2016-10-01       Impact factor: 5.590

10.  Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.

Authors:  Justyna Sosna; Stephan Philipp; Johaiber Fuchslocher Chico; Carina Saggau; Jürgen Fritsch; Alexandra Föll; Johannes Plenge; Christoph Arenz; Thomas Pinkert; Holger Kalthoff; Anna Trauzold; Ingo Schmitz; Stefan Schütze; Dieter Adam
Journal:  Mol Cell Biol       Date:  2016-09-26       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.